Stock Analysts

AT&T Raises 2012 Smartphone Goal (AAPL) (GOOG) (MSFT) (T)

Experiencing robust sales so far in the quarter and foreseeing strong demand in the coming days, AT&T ( T ) expects its 2012 smartphone sales to reach 26 million. Earlier, the company expected smartphone sales of 25 million. For the first two months of the fourth quarter, AT&T sold almost 6.4 million smartphones compared to 9.4 million for the whole of fourth quarter 2011. […]

Stock Analysts

Simon Acquires Two Outlet Centers (MAC) (SPG)

Simon Property Group, Inc. ( SPG ), a real estate investment trust (REIT), has recently acquired two upscale outlet centers in Grand Prairie, Texas and Livermore, California from an unnamed seller for an undisclosed amount. Post-acquisition, Simon Property will handle the managerial responsibilities with 100% ownership in these two centers. […]

Stock Analysts

Record Year for Toro (DE) (HMC) (TTC)

Toro Co. ( TTC ) reported break-even results in the fourth quarter of 2012, in line with the Zacks Consensus Estimate but compared unfavorably with 8 cents per share earned in the year-ago quarter. Fourth quarter results were affected by the reduced demand for snow products due to last winter's paltry snowfall, which restrained consumers to buy equipment for this season. […]

Stock Analysts

CR Bard Remains Neutral (ANGO) (BCR) (BSX) (JNJ)

We have reiterated our Neutral rating on CR Bard Inc. ( BCR ) following its third quarter results with a price target of $103. In the reported quarter, adjusted earnings of $1.64 per share surpassed the Zacks Consensus Estimate by a penny and surpassed the year-ago earnings of $1.62 per share by two cents […]

Stock Analysts

FDA Updates AZN’s Faslodex Label (AZN) (GSK) (RHHBY)

AstraZeneca ( AZN ) recently announced that it has reached an agreement with the US Food and Drug Administration (FDA) regarding label updates for Faslodex (500 mg). Faslodex (500 mg) is indicated to treat hormone receptor-positive metastatic breast cancer in postmenopausal women suffering from disease progression after antiestrogen therapy. Results along with a Kaplan-Meier plot of the final overall survival (OS) analysis from a pivotal study (CONFIRM – COmparisoN of Faslodex In Recurrent or Metastatic breast cancer) were included in the drug’s US Prescribing Information. […]